CLOs on the Move


 
STERIS is the world's pre-eminent infection prevention, decontamination, and surgical and critical care company, with a long list of first-to-market products and industry-leading service innovations and thousands of customers in more than 60 countries.
  • Number of Employees: 10K-50K
  • Annual Revenue: $250-500 Million
  • www.steris.com
  • 5960 Heisley Rd
    Mentor, OH USA 44060
  • Phone: 440.354.2600

Executives

Name Title Contact Details
Jack Ubbing
Associate General Counsel Profile
Julia Kipnis
Associate General Counsel - Information Technologies Profile
Colleen Curran
Deputy General Counsel, Compliance Profile

Similar Companies

Alchemy GS

Alchemy GS is a Mc Lean, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RTD Company

RTD Company is a Andover, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Selvita

Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within area of drug discovery, regulatory studies, as well as research and development. Selvita is also a major shareholder in Ardigen – a bioinformatics company harnessing advanced Artificial Intelligence methods for novel precision medicine. In January 2021, Selvita acquired 100% of shares in Fidelta d.o.o., substantially expanding its scope of drug discovery services in infectious diseases, inflammation, and fibrosis and building a competitive advantage in areas such as DMPK, in vivo pharmacology, and toxicology. Selvita was established in 2007 and currently employs almost 800 professionals, of which over 40% hold a Ph.D. title. Selvita is headquartered in Krakow, Poland, with a second research site in Poznan, Poland, while Fidelta is located in Zagreb, Croatia. Selvita`s international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK.

Exonics Therapeutics

Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect muscle fibers. Dystrophin is the protein missing in boys with Duchenne. The loss of dystrophin causes Duchenne.

Sangart

Sangart is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.